Summary The accuracy of immunodetection by dual parameter flow cytometry (FCM), polymerase chain reaction-mediated single strand conformation polymorphism (PCR-SSCP) and genomic sequencing to detect p53 mutations were compared. Analysis by the last two techniques was restricted to exons 5 -8. Initially, 110 breast tumours were screened for p53 expression by FCM. Seventy (64%) of tumours were immunopositive. Fifteen highly immunopositive and 15 completely immunonegative tumours were selected for further analysis by PCR-SSCP and genomic sequencing. Eleven out of 15 immunopositive tumours were found to have mutation by PCR-SSCP. Genomic sequencing confirmed the presence of mutation in 10 of these 11 immunopositive tumours. Therefore, four immunopositive tumours failed to show mutation by SSCP and five by genomic sequencing. Of the 15 immunonegative tumours, one showed mutation by both PCR-SSCP and genomic sequencing and one tumour has undergone deletion of the p53 gene. Overall, immunoreactivity correlated with both PCR-SSCP and genomic sequencing in 80% of cases (24/30), and there was 96.5% (28/ 29) concordance between PCR-SSCP and genomic sequencing. We conclude that there is good concordance between mutations detected by PCR-SSCP and genomic sequencing, but immunochemical detection of p53 overexpression is not an absolute indicator of p53 gene mutation.
Sporadic mutation of the p53 tumour-suppressor gene is the single most common genetic alteration seen in human cancer (Nigro et al., 1989) . The most commonly used methods for detection of these mutations are immunocytochemistry, polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and genomic or cDNA sequencing. Although sequencing is the most unambiguous method, it is technically cumbersome. Therefore, both immunodetection and PCR-SSCP have been widely used as alternative methods. Since the majority of p53 missense mutations are found clustered between exons 5 and 8 (Hollestein et al., 1991) , most investgators have restricted mutation analysis to this region. Missense mutations of p53 have been reported to prolong the half-life of the protein by altering its conformation (Matleshewski et al., 1986; Gannon et al., 1990; Milner and Medcalf, 1991) . Consequently, immunochemically detected p53 protein has generally been assumed to indicate an underlying p53 gene mutation. Although this has been validated in some of the earlier studies done on cell lines Bartek et al., 1990a; Rodrigues et al., 1990) and in human tumours (Davidoff et al., 1991; Thor et al., 1992; Navone et al., 1993; Deng et al., 1994) , there are reports with varying degrees of discordance between the two parameters (Allred et al., 1993; Kohler et al., 1993) . Wynford-Thomas (1992) and Hall and Lane (1994) have also cautioned against the simplisitc interpretation of p53 immunocytochemistry on account of reports of immunochemically detected wild-type p53 protein in the absence of p53 gene mutation under a wide range of conditions (Hall et al., 1993; Rasbridge et al., 1993; Lane, 1994) . It was, therefore, important to establish how closely p53 mutations observed using PCR-SSCP and immunohistochemical methods correlated with p53 gene mutations detected by sequencing and with each other.
We report here a systematic comparative analysis of p53 mutations detected by immunofluorescence using dual parameter flow cytometry, PCR-SSCP and genomic sequencing using human breast cancer tissues. Our objective was to look for the degree of concordance among the three methods of detecting p53 mutation and to verify whether immunochemical detection of p53 accumulation truly indicates the presence of p53 mutation and, if so, to what extent.
Materials and methods
Breast cancer tissues were collected immediately after surgery and transported to the laboratory on ice. After separating the fatty tissue, they were frozen at -80°C. The cell line, T-47D, SW 480 and HL-60, were obtained from the National Facility for Animal Tissue and Cell Culture, Pune, India. The first two cell lines have been reported to contain p53 mutations, while the third has a deletion of this gene. These were routinely grown in plastic T-75 flasks or on coverslips in RPMI/Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS), penicillin (100 units ml-') and streptomycin (100 ,ug ml-1). Cultures were maintained at 37°C in an atmosphere of 5% carbon dioxide. Cells grown in flasks were harvested, fixed with 0.25% cold paraformaldehyde (PFA) and used for flow cytometry. Cells grown on coverslips were fixed in 1: 1 (v/v) acetone methanol and used for immunocytochemistry.
Immunohistochemical localisation of p53 protein Specificity of PAb 1801 and Design of p53 gene-specific primers On the basis of published sequences (Gene Bank-EMBL database, accession number X54156) and previous reports (Toguchida et al., 1992) , primers specific to exons 5, 6, 7 and 8 from the intron -exon junctions were designed using oligos-4 software. Two overlapping primer pairs were chosen for exon 5. The primer pairs were selected such that they would amplify fragments that provide satisfactory resolution for detection of single base changes by SSCP.
PCR -SSCP analysis A portion of the single cell suspension prepared from human breast tissues for flow cytometry and normal human peripheral blood lymphocytes (NHPBLs) were used to extract high molecular weight DNA (Maniatis et al., 1982) .
PCR fragments corresponding to exons 5-8 of the p53 gene were generated from 50 -100 ng genomic DNA in a 100 pl reaction mixture containing 10 pmol of each primer, 150 pUM of each dNTP, 1.0 U Taq polymerase and 1 x reaction buffer. PCR was carried out for 30 cycles on a programmable thermal cycler with denaturation at 95°C for 1 min, annealing at 52 -60°C for 1 min, and extension at 72°C for 2 min. The PCR products were analysed by agarose gel electrophoresis. If additional bands were present, the fragment of interest was cut out, DNA eluted from lowmelting agarose (LMA) gel and used as a template for a second PCR reaction.
PCR-SSCP protocol was essentially the same as reported by Orita et al. (1989) with minor modifications. The second PCR for SSCP anlaysis was performed for 15 cycles under the same conditions as used for the first PCR except that 0.5 pmol of 5' end-labelled primers were used in a 10 pl reaction. Further, 1.0 pl of the labelled PCR product was diluted into 10 ,ul of sequencing stop solution with 10 mM sodium hydroxide and was heated to 95°C for 5 min. PCR products amplified from normal peripheral blood DNA were used as controls for PCR-SSCP analysis. For optimal resolution of the SSCP pattern of each exon, the run time was varied between 18 and 24 h. The samples were run at 3 W on 6% non-denaturing polyacrylamide gel with 10% glycerol at room temperature, or on MDE (AT Biochem, USA) gel as per the manufacturer's instructions.
Genomic sequencing of exons 5-8 PCR products corresponding to exons 5 and 6 were sequenced directly. Initially, the products were treated with exonuclease-I and shrimp alkaline phosphatase to remove the unused primers and dNTPs. The double stranded templates were then denatured in a thermal cycler in the presence of excess of one of the exon-specific primers. These were then snap frozen to allow rapid annealing of the primer to the template. To ensure terminations close to the primer, 3 -5 pmol of the template was extended with 10 -15-fold diluted dNTPs using PCR sequenase (USB, USA). Addition of Mn2" ions was found to improve terminations in the first 200 bp region. However, PCR products corresponding to exons 7 and 8 repeatedly gave rise to non-specific terminations resulting in high background. These products were therefore cloned into pMOS(Blue)T cloning vector (Amersham) for sequencing. The single stranded phagmids rescued with helper phage M I 3KO7 were sequenced using 0.5-1.0 pmol of both T-7 and exonspecific 5'-primer in separate reactions with sequenase V.2 (USB, USA). p53 exons cloned from normal peripheral blood DNA were used as control templates for sequencing. The sequencing reactions were run on a 6% polyacrylamide 7 M urea gel which was fixed in acetic acid, dried and exposed to Fuji xomat X-ray films for 18-24 h.
Results

Detection of p53 overexpression using flow cytometry
Immunocytochemical analysis of the cell lines and breast tumour tissues clearly indicated that the antibodies PAb 1801 and DO-7 specifically recognised nuclear accumulation of mutated p53 protein (Figure 1) . Similarly, the flow cytometric immuno-4 analysis of the three test cell lines confirmed the sensitivty of the immunofluorescence assay in which the percentage of cells overexpressing p53 protein was found to vary according to the corresponding genetic abnormality. Thus, both T-47D and SW 480 with known mutations in exon 6 and 9 respectively, had 80-90% of cells overexpressing the protein, whereas only 0.3% of HL-60 cells with a deleted p53 gene were found to express the protein (Figure 2 ). In addition, the specificity of the assay could be increased by gating the immunofluorescence events on the basis of their DNA profile, thereby reducing the background fluorescence to a minimum. As expected p53 specific immunofluorescence could be seen confined to cells not only in GI and S, but also in G2/M phases of the cell cycle owing to stabilisation of the mutant protein.
A total of 110 breast tumours were analysed for p53 expression. Forty (36%) tumours were found to have less than 5% p53-positive cells and were classified as immunonegative. Seventy (64%) tumours had more than 5% p53-positive cells and were considered immunopositive. Of these, 15 tumours had more than 15% p53-positive cells. These were classified as highly immunopositive. (Figure 3) . Although the exon 6 mutation of T47D could be resolved on PAGE, none of the breast tumours showed mobility shift for exon 6 on PAGE. These findings prompted us to try the mutation detection and enhancement (MDE) gel. which has been reported to enhance resolution of SSCP patterns, particularly of exon 6 (Soto and Sukumar, 1992). Two out of 15 tumours showed mobility shift under these conditions (Figure 3) . Overall, PCR-SSCP detected mutations in 40% (12 30) carcinomas. Eleven of these 12 mutations were in immunopositive tumours and one in inmunonegative tumour. The distribution of these mutations was six in exon 5, two in exon 6, three in exon 7 and one in exon 8 (Figures 3 and 4) . These mutations were present in all four exons analysed (Table I) . Exon 5 showed mutation in five tumours, exon 6 in two, exon 7 in three and exon 8 in one tumour. The majority of these mutations were base substitution mutations ( Figure  5 ). However, one tumour in exon 7 showed a frameshift mutation ( Figure 5 ) and one immunonegative tumour had deletion of the p53 gene. The latter, therefore, could not be used for PCR-SSCP and sequencing. All the rest had wildtype sequence.
Correlation between immunochemical detection of p53, PCR-SSCP and p53 gene mutation Eleven out of 15 immunopositive tumours were found to have mutation by PCR-SSCP. Genomic sequencing confirmed the presence of mutation in ten of these 11 tumours. Thus, one immunopositive tumour that did show mutation in exon 5 by SSCP, however, failed to show mutation on sequencing. Since exon 5 had been amplified in two overlapping fragments, it is unlikely that we would have human peripheral blood lymphocyte (NHPBL). BT-2, BT-3 and BT-4 show mobility shifts for exon 5. All the three-tumours (BT-1, and BT-8) show mobility shift for exon 7, whereas only BT-l 1 shows mobility shift for exon 8. Numbers represent breast tumours given in Table I . For details, refer to the Materials and results sections. (1990b) . However, it was observed that cultured cells without formalin fixation produced better staining patterns. Hence, we analysed p53 expression by dual parameter flow cytometry, which involved only mild fixation in paraformaldehyde. Moreover, the flow cytometric immunofluorescence assay used was found to be quantitative and highly specific as it monitors p53 expression and its DNA content simultaneously, thereby minimising background fluorescence. It also enabled visual confirmation of GI -S phase-specific p53 expression.
Sixty-four per cent of tumours were found to be immunopositive by the flow cytometric assay as against 20-57% reported in earlier studies (Cattriotie et al., 1988; Bartek et al., 1990; Davidoff et al., 1991; Deng et al., 1994 Table I. staining in all the ceHls (DaVidoff et al.. 1991 
